Preferred Label : Urabrelimab;
NCIt synonyms : Anti-CD47 Monoclonal Antibody SRF231;
NCIt definition : A human monoclonal antibody targeting the human cell surface antigen CD47, with potential
phagocytosis-inducing and antineoplastic activities. Upon administration, urabrelimab
selectively binds to CD47 on tumor cells and blocks the interaction of CD47 with signal
regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages.
This prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPa-mediated
inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the
binding of calreticulin (CRT), which is specifically expressed on the surface of tumor
cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed
on macrophages. This results in macrophage activation and the specific phagocytosis
of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor
T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor
cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated
antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed
on the surface of a variety of cancer cells. Expression of CD47, and its interaction
with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer
cells from phagocytosis, which allows cancer cells to proliferate.;
UNII : W6284A5K8N;
CAS number : 2249722-58-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2249722-58-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : SRF 231; SRF-231;
NCI Metathesaurus CUI : CL562712;
Origin ID : C155976;
UMLS CUI : C5418254;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
